Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial - The Lancet Neurology
PDF) Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study
1.0 Abstract
PDF) Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study
AbbVie to present new and updated data from 22 abstracts
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
All Crohn's disease patient selection results. Abbreviations: CD,... | Download Scientific Diagram
Biogen Ends Trial of Its Drug for PSP - CurePSP
Participation in an innovative patient support program reduces prescri | PPA
AbbVie Ends Tau Antibody Study - CurePSP
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
Participation in an innovative patient support program reduces prescri | PPA
PSP and CBD Research
Summary of Clinical Trial Results
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
1.0 Abstract
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab? - ACR Meeting Abstracts
PDF) Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States
1.0 Abstract
AbbVie's Five Biggest Priorities, Apart From Allergan :: Scrip
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares - ACR Meeting Abstracts
AbbVie takes anti-tau drug into phase II for Alzheimer's - PMLiVE
PDF) Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
1. Abstract
Dr. Bower receives research funding from Abbvie Pharmaceuticals for a clinical trial on PSP Mr. T is a 66 year old man,
